ReviewCurrent aging science2026
Biomarkers for Chronic Kidney Disease: An Updated Review of Innovative Detection Approaches.
Review in Current aging science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High frailty index scores predict mortality and changes in blood-based biomarkers in aging female mice.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic kidney disease (CKD) is a progressive and incurable condition that impairs kidney function over time. Affecting approximately 13% of the global population, CKD poses a substantial economic burden on healthcare systems and significantly reduces both the quality and duration of life for affected individuals. The overview of innovative methods will facilitate the identification and documentation of novel biomarkers associated with kidney diseases.
aimThis review summarizes the findings of previous studies associated with novel therapeutic approaches and biomarkers for the early detection of CKD. MATERIALS AND
methodsAll relevant databases were searched for published articles on the topic of interest from the beginning of the study period up to April 2025, using the following search terms: "Chronic Kidney Disease," "Conventional Biomarkers," and "Novel Biomarkers." We also reviewed the reference lists of eligible studies, previous review articles, and registered clinical trials. A total of 101 manuscripts were included in this evaluation.
resultsTo comprehensively understand the diverse changes resulting from the complex pathomechanisms of CKD, the use of a combination of biomarkers is recommended. Relying solely on creatinine levels, estimated glomerular filtration rate (eGFR), and proteinuria may be insufficient for accurate diagnosis. However, for the diagnosis, monitoring of progression, and assessment of disease severity, direct measurement of glomerular filtration rate (GFR) remains the most reliable and optimal approach. Glomerular, tubular, and tissue integrity of endothelial and epithelial cells in the nephron could be representative of morphophysiological changes associated with CKD. Albumin and creatinine are not sufficient for clinical application in the early detection of CKD. The published articles reported urea/BUN, creatinine, and cystatin C as the functional biomarkers. Injury biomarkers included: proteinuria, hematuria, creatinine (when > 40% kidney parenchyma is damaged), cystatin C, podocytes, podocalyxin, Nephrin, Podocin, CR1, CD80, synaptopodin, GLEPP-1, CD59, WT1, and CD59. For CKD progression, measuring DKK3, CKD273, hL-FABP, Fetuin-A, and Scd25 might offer valuable information.
conclusionDifferent biomarkers should be deliberated regarding the early detection of CKD based on their sensitivity, efficacy, specificity, and, of course, cost benefits for both patients and health system decision makers, which confer relevance.
Indexed as
Identifiers
40692154What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.